1.	Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
2.	Phase III Randomized Study of Interferon alfa Versus CCI-779 Versus Interferon alfa and CCI-779 in Patients With Poor Prognosis Stage IV or Recurrent Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0305091, WYETH-C-3066K1-304-WW, NCT00065468
3.	Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-305, UCLA-0502046-01A, WYETH-3066K1-305-WW, NCT00117598
4.	Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-404, B1771003, NCT00474786
5.	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-3311, B1771006, NCT00631371
6.	CCI-779 in Treating Patients With Malignant Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068848, NABTC-0101, NCT00022724
7.	Phase I/II Study of CCI-779 and Bevacizumab in Patients With Metastatic or Unresectable Renal Cell Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0452, NCI-6986, 6986, NCT00112840
8.	Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ABTC-0402 CDR0000429553, U01CA062399, ABTC-0402, NCI-06-C-0053, NABTC-04-02, NCT00112736
9.	Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00652, N0572, CDR0000472240, NCCTG-N0572, U10CA025224, NCT00329719
10.	Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00676, NABTC-05-02, CDR0000476286, U01CA137443, ABTC-05-02, NCT00335764
11.	Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00131, U01CA062461, 2005-0215, MDA-2005-0215, 7149, NCI-7149, NCT00349206
12.	Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 06-365, NCT00483262
13.	Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000619329, NCCTG-N078D, N078D, NCT00787969
14.	Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: 2008-0827, NCT00877773
15.	Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 09-0668 / 201105207, NCT00921310
16.	Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 1 and over Sponsor: Other Protocol IDs: J0963, NA_00028490, NCT00949325
17.	Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01406, 09-117, U01CA069856, MSKCC-09117, IRB #09-117, 8147, NCT01026623
18.	Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01409, 09-058, U01CA069856, MSKCC-09058, 8249, NCT01051557
19.	Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CASE7808, NCI-2010-00308, CASE7808-CC527, NCT01083368
20.	Hepatocellular Carcinoma (HCC)_Torisel_ Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: HCC022, NCT01251458
21.	CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00109, MC0452, N01CM17104, NCT00112840
22.	Phase II Randomized Study of CCI-779 in Patients With Androgen-Independent Prostate Cancer (Summary Last Modified 05/2002) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-000606401, GENE-C9940-32, UCLA-CCI-779, W-AR-3066K1-201-US, NCI-G01-1917, NCT00012142
23.	CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01858, N997B, U10CA025224, CDR0000068623, NCCTG-N997B, NCT00016328
24.	CCI-779 in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068820, U01CA063265, P30CA033572, CHNMC-PHII-27, CHNMC-IRB-99167, NCI-29, 29, NCT00022464
25.	CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01870, N0186, U10CA025224, CDR0000069269, NCCTG-N0186, NCT00033267